Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Aug 1;381(1):102-15.
doi: 10.1016/j.jmb.2008.05.062. Epub 2008 Jul 1.

Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir

Affiliations

Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir

Fengling Liu et al. J Mol Biol. .

Abstract

HIV-1 (human immunodeficiency virus type 1) protease (PR) and its mutants are important antiviral drug targets. The PR flap region is critical for binding substrates or inhibitors and catalytic activity. Hence, mutations of flap residues frequently contribute to reduced susceptibility to PR inhibitors in drug-resistant HIV. Structural and kinetic analyses were used to investigate the role of flap residues Gly48, Ile50, and Ile54 in the development of drug resistance. The crystal structures of flap mutants PR(I50V) (PR with I50V mutation), PR(I54V) (PR with I54V mutation), and PR(I54M) (PR with I54M mutation) complexed with saquinavir (SQV) as well as PR(G48V) (PR with G48V mutation), PR(I54V), and PR(I54M) complexed with darunavir (DRV) were determined at resolutions of 1.05-1.40 A. The PR mutants showed changes in flap conformation, interactions with adjacent residues, inhibitor binding, and the conformation of the 80s loop relative to the wild-type PR. The PR contacts with DRV were closer in PR(G48V)-DRV than in the wild-type PR-DRV, whereas they were longer in PR(I54M)-DRV. The relative inhibition of PR(I54V) and that of PR(I54M) were similar for SQV and DRV. PR(G48V) was about twofold less susceptible to SQV than to DRV, whereas the opposite was observed for PR(I50V). The observed inhibition was in agreement with the association of G48V and I50V with clinical resistance to SQV and DRV, respectively. This analysis of structural and kinetic effects of the mutants will assist in the development of more effective inhibitors for drug-resistant HIV.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(a) The chemical structures of saquinavir and darunavir. (b) Structure of HIV-1 PR dimer with the locations of mutated residues Gly48 (cyan), Ile50 (red), Ile54 (green) indicated by spheres for main chain atoms in both subunits. Darunavir is shown in sticks colored by atom type. The flap residues (45–55) and the 80’s loop (78–82) are colored in blue and purple, respectively.
Figure 2
Figure 2
The Fo-Fc omit maps showing the mutated residues and the flap residues (47–54) contoured at 3.3 sigma. Val 48 is from PRG48V-DRV, Val50 from PRI50V-SQV, Val54 from PRI54V-SQV, Met54 from PRI54M-SQV and flap residues from PRI54M-SQV. The cyan sticks indicate the alternate conformations of main-chain and side-chain atoms in Val50 and Met54.
Figure 3
Figure 3
The Fo-Fc omit maps of saquinavir (upper panel) and darunavir (lower panel) contoured at 3.3 sigma. Saquinavir is colored by atom type from complex PRI54V-SQV. Darunavir is from complex PRI54V-DRV showing alternate conformations of 60/40% occupancy. The major conformation is colored by atom type and the minor is colored pink.
Figure 4
Figure 4
The flap regions for superimposed complexes with darunavir. The wild type PR is in green, PRG48V in cyan, PRI54V in magenta and PRI54M in red. The arrows indicate the shifts between Cα atoms of PRG48V and of the wild type PR with distances in Å.
Figure 5
Figure 5
PRI54M interactions with inhibitor. (a) The major orientation of saquinavir. (b) The major orientation of darunavir. Hydrogen bonds are indicated in red, CH-π interactions in blue and C-H…O in purple. Interatomic distances are shown in Å. Note that the water-mediated interaction of the NH2 of darunavir with the Asp30 side chain is replaced by a direct hydrogen bond in the wild type PR and the other mutant structures.
Figure 6
Figure 6
(a) Comparison of the flaps of PRG48V-DRV and of wild type PR-DRV in the two subunits. (b) Selected PRG48V interactions with darunavir in the minor conformation. The mutant structures are colored by atom type and wild type PR is in grey. Dashed lines indicate van der Waals interactions with interatomic distances shown in Å. The arrows show the shift between the two structures with distances in Å.
Figure 6
Figure 6
(a) Comparison of the flaps of PRG48V-DRV and of wild type PR-DRV in the two subunits. (b) Selected PRG48V interactions with darunavir in the minor conformation. The mutant structures are colored by atom type and wild type PR is in grey. Dashed lines indicate van der Waals interactions with interatomic distances shown in Å. The arrows show the shift between the two structures with distances in Å.
Figure 7
Figure 7
The interactions of residues 50, 51, 54 and 79–81 in (a) PRI50V-SQV, (b) PRI54M-DRV, and (c) PRI54V-DRV. The structures of mutants are colored by atom types and the corresponding structures of wild type PR are grey. Dashed lines indicate van der Waals interactions with interatomic distances shown in Å. The arrows show the shift between the two structures with distances in Å.
Figure 7
Figure 7
The interactions of residues 50, 51, 54 and 79–81 in (a) PRI50V-SQV, (b) PRI54M-DRV, and (c) PRI54V-DRV. The structures of mutants are colored by atom types and the corresponding structures of wild type PR are grey. Dashed lines indicate van der Waals interactions with interatomic distances shown in Å. The arrows show the shift between the two structures with distances in Å.

Similar articles

Cited by

References

    1. Miller M, Schneider J, Sathyanarayana BK, Toth MV, Marshall GR, Clawson L, Selk L, Kent SB, Wlodawer A. Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 A resolution. Science. 1989;246:1149–52. - PubMed
    1. Gustchina A, Weber IT. Comparison of inhibitor binding in HIV-1 protease and in non-viral aspartic proteases: the role of the flap. FEBS. 1990;269:269–272. - PubMed
    1. Ishima R, Freedberg DI, Wang YX, Louis JM, Torchia DA. Flap opening and dimer-interface flexibility in the free and inhibitor-bound HIV protease. Structure. 1999;7:1047–55. - PubMed
    1. Shao W, Everitt L, Manchester M, Loeb DD, Hutchison CA, 3rd, Swanstrom R. Sequence requirements of the HIV-1 protease flap region determined by saturation mutagenesis and kinetic analysis of flap mutants. Proc Natl Acad Sci. 1997;94:2243–8. - PMC - PubMed
    1. Shafer RW. Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev. 2002;15:247–77. - PMC - PubMed

Publication types